Regulus Historical Financial Ratios

RGLS Stock

USD 1.64 0.07 4.46%

Regulus Therapeutics is promptly reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.17, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.22 will help investors to properly organize and evaluate Regulus Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

About Regulus Financial Ratios Analysis

Regulus TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Regulus Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Regulus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Regulus Therapeutics history.

Regulus Therapeutics Financial Ratios Chart

At this time, Regulus Therapeutics' Shareholders Equity Per Share is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.07 in 2024, whereas Days Sales Outstanding is likely to drop 15.69 in 2024.

Price To Sales Ratio Ptb Ratio Ev To Sales Free Cash Flow Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Regulus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Regulus Therapeutics sales, a figure that is much harder to manipulate than other Regulus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most ratios from Regulus Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Regulus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.At this time, Regulus Therapeutics' Shareholders Equity Per Share is comparatively stable compared to the past year. Debt To Equity is likely to gain to 0.07 in 2024, whereas Days Sales Outstanding is likely to drop 15.69 in 2024.

	2023	2024 (projected)
Graham Number	6.31	6.0
Receivables Turnover	22.88	42.26

Graham Number Receivables Turnover

Regulus Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.15	0.98	0.14	0.02	0.01	-0.28	0.15	1.0	0.02	-0.2	0.18	0.13	-0.13	-0.1	0.99	-0.15	0.08	0.09	0.03	0.08	-0.16	-0.01	-0.14	0.0	0.1
Ptb Ratio	0.15		0.15	0.38	0.23	0.02	-0.2	1.0	0.12	0.06	0.36	0.13	0.33	-0.07	0.12	0.12	-0.35	-0.85	-0.82	-0.21	-0.86	-0.19	0.08	-0.49	-0.84	-0.78
Days Sales Outstanding	0.98	0.15		0.15	0.03	0.01	-0.29	0.15	0.97	0.02	-0.18	0.22	0.14	-0.12	-0.11	0.99	-0.17	0.14	0.12	0.03	0.14	-0.15	-0.01	-0.2	0.07	0.15
Book Value Per Share	0.14	0.38	0.15		0.13	0.08	-0.43	0.38	0.13	0.2	-0.37	0.62	0.93	0.14	0.23	0.09	-1.0	-0.31	-0.2	-0.55	-0.31	-0.04	0.16	-0.05	-0.21	-0.28
Free Cash Flow Yield	0.02	0.23	0.03	0.13		0.96	0.5	0.23	0.01	0.96	0.19	0.02	-0.22	0.03	0.01	0.06	-0.12	-0.16	-0.13	0.5	-0.15	0.0	-0.85	-0.25	-0.12	-0.15
Operating Cash Flow Per Share	0.01	0.02	0.01	0.08	0.96		0.53	0.02	0.01	0.99	-0.04	0.06	-0.27	0.02	0.03	0.04	-0.09	-0.01	-0.02	0.59	-0.01	0.0	-0.89	0.0	-0.01	-0.01
Capex To Depreciation	-0.28	-0.2	-0.29	-0.43	0.5	0.53		-0.2	-0.27	0.47	0.22	-0.26	-0.59	-0.31	0.34	-0.24	0.42	0.23	0.14	0.51	0.24	-0.19	-0.63	-0.2	0.19	0.24
Pb Ratio	0.15	1.0	0.15	0.38	0.23	0.02	-0.2		0.12	0.06	0.36	0.13	0.33	-0.07	0.12	0.12	-0.35	-0.85	-0.82	-0.21	-0.86	-0.19	0.08	-0.49	-0.84	-0.78
Ev To Sales	1.0	0.12	0.97	0.13	0.01	0.01	-0.27	0.12		0.02	-0.22	0.18	0.12	-0.13	-0.1	0.98	-0.14	0.09	0.09	0.03	0.09	-0.16	-0.01	-0.11	0.01	0.11
Free Cash Flow Per Share	0.02	0.06	0.02	0.2	0.96	0.99	0.47	0.06	0.02		-0.08	0.13	-0.16	0.04	0.06	0.05	-0.2	-0.04	-0.04	0.53	-0.04	0.0	-0.86	-0.01	-0.03	-0.04
Roic	-0.2	0.36	-0.18	-0.37	0.19	-0.04	0.22	0.36	-0.22	-0.08		-0.44	-0.36	0.12	-0.3	-0.15	0.4	-0.28	-0.22	0.04	-0.28	0.21	-0.04	-0.73	-0.22	-0.28
Inventory Turnover	0.18	0.13	0.22	0.62	0.02	0.06	-0.26	0.13	0.18	0.13	-0.44		0.61	0.18	0.21	0.14	-0.68	0.09	-0.03	-0.03	0.08	-0.01	0.03	-0.03	0.05	0.21
Net Income Per Share	0.13	0.33	0.14	0.93	-0.22	-0.27	-0.59	0.33	0.12	-0.16	-0.36	0.61		0.15	0.24	0.06	-0.94	-0.26	-0.16	-0.71	-0.26	-0.03	0.48	-0.05	-0.17	-0.24
Days Of Inventory On Hand	-0.13	-0.07	-0.12	0.14	0.03	0.02	-0.31	-0.07	-0.13	0.04	0.12	0.18	0.15		-0.24	-0.14	-0.17	0.13	0.21	0.03	0.13	0.93	0.09	-0.11	0.16	0.13
Payables Turnover	-0.1	0.12	-0.11	0.23	0.01	0.03	0.34	0.12	-0.1	0.06	-0.3	0.21	0.24	-0.24		-0.13	-0.26	0.06	-0.01	-0.08	0.06	-0.29	0.02	-0.12	0.04	0.02
Capex To Revenue	0.99	0.12	0.99	0.09	0.06	0.04	-0.24	0.12	0.98	0.05	-0.15	0.14	0.06	-0.14	-0.13		-0.1	0.13	0.14	0.07	0.13	-0.16	-0.06	-0.18	0.06	0.14
Cash Per Share	-0.15	-0.35	-0.17	-1.0	-0.12	-0.09	0.42	-0.35	-0.14	-0.2	0.4	-0.68	-0.94	-0.17	-0.26	-0.1		0.26	0.17	0.5	0.26	0.03	-0.17	0.05	0.17	0.24
Pocfratio	0.08	-0.85	0.14	-0.31	-0.16	-0.01	0.23	-0.85	0.09	-0.04	-0.28	0.09	-0.26	0.13	0.06	0.13	0.26		0.89	0.3	1.0	0.19	-0.08	0.11	0.97	0.91
Interest Coverage	0.09	-0.82	0.12	-0.2	-0.13	-0.02	0.14	-0.82	0.09	-0.04	-0.22	-0.03	-0.16	0.21	-0.01	0.14	0.17	0.89		0.12	0.9	0.24	-0.06	0.07	0.9	0.81
Capex To Operating Cash Flow	0.03	-0.21	0.03	-0.55	0.5	0.59	0.51	-0.21	0.03	0.53	0.04	-0.03	-0.71	0.03	-0.08	0.07	0.5	0.3	0.12		0.28	0.04	-0.58	0.09	0.17	0.21
Pfcf Ratio	0.08	-0.86	0.14	-0.31	-0.15	-0.01	0.24	-0.86	0.09	-0.04	-0.28	0.08	-0.26	0.13	0.06	0.13	0.26	1.0	0.9	0.28		0.19	-0.09	0.12	0.97	0.91
Days Payables Outstanding	-0.16	-0.19	-0.15	-0.04	0.0	0.0	-0.19	-0.19	-0.16	0.0	0.21	-0.01	-0.03	0.93	-0.29	-0.16	0.03	0.19	0.24	0.04	0.19		0.06	-0.1	0.21	0.2
Income Quality	-0.01	0.08	-0.01	0.16	-0.85	-0.89	-0.63	0.08	-0.01	-0.86	-0.04	0.03	0.48	0.09	0.02	-0.06	-0.17	-0.08	-0.06	-0.58	-0.09	0.06		0.02	-0.04	-0.22
Roe	-0.14	-0.49	-0.2	-0.05	-0.25	0.0	-0.2	-0.49	-0.11	-0.01	-0.73	-0.03	-0.05	-0.11	-0.12	-0.18	0.05	0.11	0.07	0.09	0.12	-0.1	0.02		0.07	0.1
Ev To Operating Cash Flow	0.0	-0.84	0.07	-0.21	-0.12	-0.01	0.19	-0.84	0.01	-0.03	-0.22	0.05	-0.17	0.16	0.04	0.06	0.17	0.97	0.9	0.17	0.97	0.21	-0.04	0.07		0.83
Pe Ratio	0.1	-0.78	0.15	-0.28	-0.15	-0.01	0.24	-0.78	0.11	-0.04	-0.28	0.21	-0.24	0.13	0.02	0.14	0.24	0.91	0.81	0.21	0.91	0.2	-0.22	0.1	0.83

Click cells to compare fundamentals

Regulus Therapeutics Account Relationship Matchups

Regulus Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	1.1K	112.61	2.25	4.72	4.25	4.03
Ptb Ratio	0.77	1.81	0.5	0.63	1.15	1.75
Days Sales Outstanding	1.9K	131.81	60.96	18.35	16.51	15.69
Book Value Per Share	11.6	7.44	6.41	2.18	1.12	1.17
Free Cash Flow Yield	(1.31)	(0.27)	(0.89)	(1.24)	(1.13)	(1.18)
Operating Cash Flow Per Share	(11.48)	(3.58)	(2.82)	(1.67)	(1.41)	(1.48)
Stock Based Compensation To Revenue	106.14	75.57	0.33	0.26	0.24	0.22
Capex To Depreciation	0.26	0.0236	0.55	2.96	2.7	2.84
Pb Ratio	0.77	1.81	0.5	0.63	1.15	1.75
Ev To Sales	1.2K	149.28	(0.6)	2.08	1.87	1.78
Free Cash Flow Per Share	(11.63)	(3.59)	(2.84)	(1.7)	(1.44)	(1.52)
Roic	(0.49)	(0.45)	(0.47)	(0.75)	(1.38)	(1.45)
Inventory Turnover	0.003147	0.004631	152.49	40.53	7.03	7.38
Net Income Per Share	(10.77)	(4.36)	(3.24)	(1.86)	(1.58)	(1.66)
Days Of Inventory On Hand	116.0K	78.8K	2.39	9.01	51.94	49.34
Payables Turnover	0.009348	0.0287	1.61	0.7	103.69	108.87
Sales General And Administrative To Revenue	236.26	178.61	1.66	0.88	0.79	0.75
Capex To Revenue	4.43	0.31	0.0357	0.001099	9.89E-4	9.4E-4
Cash Per Share	19.77	8.89	7.05	2.57	1.25	1.19
Pocfratio	(0.78)	(3.77)	(1.14)	(0.82)	(0.91)	(0.95)
Interest Coverage	(7.9)	(7.83)	(32.53)	(41.05)	(51.5)	(54.08)
Capex To Operating Cash Flow	(0.0123)	(8.77E-4)	(0.0104)	(0.0141)	(0.0229)	(0.024)
Pfcf Ratio	(0.77)	(3.76)	(1.12)	(0.81)	(0.89)	(0.93)
Days Payables Outstanding	39.0K	12.7K	226.63	523.57	3.52	3.34
Roe	(0.93)	(0.59)	(0.51)	(0.85)	(1.42)	(1.35)
Ev To Operating Cash Flow	(0.25)	0.21	(1.66)	1.07	(0.12)	(0.11)
Pe Ratio	(0.83)	(3.09)	(0.99)	(0.74)	(0.81)	(0.85)
Return On Tangible Assets	(1.78)	(0.44)	(0.41)	(0.61)	(0.98)	(1.03)
Ev To Free Cash Flow	(1.43)	(0.25)	0.21	(1.66)	1.06	(0.11)
Earnings Yield	(1.21)	(0.32)	(1.01)	(1.35)	(1.24)	(1.3)
Intangibles To Total Assets	0.006321	0.003324	0.001212	0.001327	0.001073	0.00102
Net Debt To E B I T D A	1.26	1.96	1.95	0.64	0.69	0.66
Current Ratio	1.87	3.17	12.48	3.78	3.31	3.15
Tangible Book Value Per Share	11.44	7.41	6.4	2.18	1.12	1.17
Receivables Turnover	0.19	2.77	5.99	19.89	22.88	42.26
Graham Number	53.01	27.03	21.64	9.54	6.31	6.0
Shareholders Equity Per Share	11.6	7.44	6.41	2.18	1.12	1.17

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Cash Conversion Cycle

Regulus Historical Financial Ratios

About Regulus Financial Ratios Analysis

Regulus Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Ev To Sales

Free Cash Flow Per Share

Regulus Therapeutics fundamentals Correlations

Regulus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regulus Therapeutics fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Regulus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Pocfratio
Capex To Revenue	+ 0.99	Price To Sales Ratio
Capex To Revenue	+ 0.99	Days Sales Outstanding
Free Cash Flow Per Share	+ 0.99	Operating Cash Flow Per Share

Cash Per Share	- 1.0	Book Value Per Share
Cash Per Share	- 0.94	Net Income Per Share
Income Quality	- 0.89	Operating Cash Flow Per Share
Income Quality	- 0.86	Free Cash Flow Per Share
Pfcf Ratio	- 0.86	Pb Ratio
Pfcf Ratio	- 0.86	Ptb Ratio